DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

Rhea-AI Summary

DeepHealth (Nasdaq: RDNT) unveiled an expanded portfolio of imaging informatics and clinical AI solutions at RSNA 2025 on November 30, 2025. The announcement highlights integrations across Diagnostic Suite, TechLive, Operations Suite and modality-specific Clinical AI suites (Breast, Thyroid, Neuro, Chest, Prostate) running on DeepHealth OS to unify imaging workflows, reporting and AI orchestration.

Notable disclosed impacts include 400+ scanners connected to TechLive, 42% fewer MR room closures, support for > 10 million mammograms annually, a Nature Health analysis showing 21% higher breast cancer detection in 579,000 women, deployment at > 200 sites for Thyroid Suite, and > 2,000 customers with 5,000+ radiologists using DeepHealth solutions.

Positive

• TechLive connected >400 scanners to remote management
• TechLive associated with 42% fewer MR room closures
• Breast Suite supports >10 million mammograms annually
• Nature Health study: 21% higher breast cancer detection
• Thyroid Suite deployed across >200 RadNet sites
• Portfolio used by >2,000 customers and 5,000+ radiologists

Negative

• Chest Suite applications are US 510(k)-pending, limiting US availability
• Prostate Suite lesion detection and classification are 510(k)-pending

Key Figures

Connected scanners: 400 scanners MR room closure reduction: 42% fewer Annual mammograms supported: 10 million+ +5 more

8 metrics

Connected scanners 400 scanners RadNet deployment of TechLive remote imaging

MR room closure reduction 42% fewer Impact of TechLive deployment at RadNet

Annual mammograms supported 10 million+ Breast Suite applications usage globally

Study population 579,000+ women Largest real-world AI breast screening analysis in Nature Health

Detection rate increase 21% increase Breast cancer detection rate improvement with Breast Suite applications

Earlier-stage lung cancers 76% vs 29% NHS England lung program outcomes with Chest Suite-related solution

RadNet thyroid sites 200+ sites Deployment of Thyroid Suite across RadNet

AI measurement acceptance 94%+ cases Radiologists accepting Thyroid Suite AI outputs on 4,070+ nodules

Market Reality Check

Price: $72.00 Vol: Volume 989,968 is above t...

normal vol

$72.00 Last Close

Volume Volume 989,968 is above the 20-day average of 862,927, indicating elevated interest ahead of/around the RSNA update. normal

Technical Price 78.66 is trading above the 200-day MA of 63.47, reflecting a pre-existing uptrend into this AI portfolio expansion.

Peers on Argus

RDNT gained 1.69% while key diagnostics peers were mixed: GH -2.86%, WGS -1.8%, ...

RDNT gained 1.69% while key diagnostics peers were mixed: GH -2.86%, WGS -1.8%, SHC +0.3%, RVTY +0.38%, CRL -0.26%. The move appeared more company-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Product launch	Positive	-3.4%	Launch of Breast Suite AI platform for breast cancer detection and workflow.
Nov 20	Customer win	Positive	-1.3%	Wichita Radiological Group selects Operations Suite under five-year agreement.
Nov 17	Clinical data	Positive	+2.8%	Nature Health ASSURE study shows higher AI breast cancer detection rates.
Nov 12	Strategic collaboration	Positive	-1.3%	Expanded GE HealthCare collaboration across modalities and remote scanning.
Nov 11	Acquisition	Positive	-2.9%	Acquisition of CIMAR UK to bolster AI-powered imaging in UK and Europe.

Pattern Detected

Recent AI and DeepHealth news has generally been positive but often met with modest or even negative next-day price reactions, indicating uneven alignment between strong product news and share moves.

Recent Company History

Over the last months, RadNet’s DeepHealth unit has advanced a broad AI imaging strategy. On Nov 11, it acquired CIMAR UK to extend cloud image management in the UK and Europe. Subsequent AI collaborations with GE HealthCare and a landmark Nature Health study on AI breast screening highlighted clinical impact, while Operations Suite and Breast Suite launches signaled commercialization efforts. Today’s RSNA 2025 announcement extends this trajectory by unifying and expanding these AI-powered imaging suites under one integrated portfolio.

Market Pulse Summary

This announcement details a broad RSNA 2025 expansion of DeepHealth’s AI-powered imaging portfolio, ...

Analysis

This announcement details a broad RSNA 2025 expansion of DeepHealth’s AI-powered imaging portfolio, spanning Diagnostic, Operations, Breast, Thyroid, Neuro, Chest and Prostate Suites, all unified under DeepHealth OS. It builds on earlier acquisitions like iCAD and See‑Mode and large-scale clinical validation in breast and lung screening. Investors may watch real-world deployment metrics such as connected scanners, acceptance rates of AI outputs, and uptake among the company’s 2,000+ customers and 5,000+ radiologists.

Key Terms

510(k) clearance, white matter hyperintensity, volumetric measurement, pulmonary nodule, +4 more

8 terms

510(k) clearance regulatory

"With first-of-kind 510(k) clearance, it extends expert oversight across MR..."

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

white matter hyperintensity medical

"Brain Health for white matter hyperintensity (WMH) detection and segmentation..."

Small bright spots seen on brain MRI that show areas where white matter — the wiring that connects different brain regions — has been damaged or altered, often from aging, blood vessel changes, or other health conditions. Investors care because their presence predicts higher risk of stroke, cognitive decline and disability, which can influence demand for drugs, diagnostics, long‑term care costs and the outcomes of clinical trials, similar to spotting rust on a machine that signals hidden wear and future repair costs.

volumetric measurement medical

"Brain Health for white matter hyperintensity (WMH) detection and... Brain Age for volumetric measurement."

Volumetric measurement is the quantification of a physical quantity by the amount of three-dimensional space it occupies—for example liters, gallons, or cubic meters—rather than by count or weight. Investors care because reporting output, inventory, sales or doses by volume gives a clearer picture of production capacity, resource use and pricing dynamics (like how much product a facility can produce or how much liquid medicine was shipped), which affects revenue forecasts, margins and regulatory compliance.

pulmonary nodule medical

"applications of the expanded Chest Suite... automate pulmonary nodule detection, characterization..."

A pulmonary nodule is a small, round or oval spot seen on a lung scan, typically no larger than a cherry, that may be harmless or signal infection, inflammation, or a developing disease. For investors, nodules matter because they can lead to follow-up tests, treatments, or medical products and regulatory decisions that affect the revenue and valuation of healthcare companies tied to diagnostics, imaging, drugs or devices.

PI-RADS-compliant medical

"integrates automated lesion detection and risk classification... and PI-RADS-compliant reporting..."

PI-RADS-compliant means a prostate MRI scan, reporting tool or imaging product follows the PI-RADS standardized rules for how images are taken, read and scored for signs of prostate cancer. For investors this matters because compliance is like meeting a common recipe or grading scale for doctors—it makes results more consistent, helps products win clinical acceptance, supports regulatory and reimbursement pathways, and can speed adoption in hospitals and clinics.

fusion biopsy systems medical

"connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer..."

Fusion biopsy systems are medical devices that combine two different types of medical images — for example, a high-detail scan and a live ultrasound — to guide a needle to a suspicious spot more precisely. For investors, they matter because better targeting can raise the accuracy and efficiency of biopsies, reduce repeat procedures, and influence demand, reimbursement and competitive positioning in the diagnostic tools market.

drift management technical

"includes governance tools for AI evaluation, monitoring and drift management in production..."

Drift management is the ongoing process of monitoring and correcting changes in an investment portfolio's target mix that occur as market prices move. Like a captain trimming the sails to keep a boat on course, it involves rebalancing holdings so risk and return stay aligned with an investor's goals; without it a portfolio can slowly become either too risky or too conservative, affecting expected performance and downside protection.

cloud-native technical

"DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics..."

Cloud-native describes a way of creating and running applications that are designed specifically to operate smoothly on cloud computing platforms. Think of it as building a house with flexible, lightweight materials that can be easily moved, scaled, or adjusted as needed, rather than using rigid, traditional construction. For investors, it signifies technology that is more adaptable, efficient, and capable of quickly responding to changing market demands.

AI-generated analysis. Not financial advice.

Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imaging

CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company is announcing new offerings and major enhancements across its portfolio, spanning disease detection, assessment and monitoring, remote scanning, image management and interpretation, center operations and AI orchestration—all designed to transform the imaging experience and advance population health.

“We are entering an era where AI-powered imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “At DeepHealth, we harness AI in an integrated, end-to-end approach across our portfolio with the intent to improve healthcare delivery. By unifying clinical and operational intelligence into DeepHealth OS and deploying scalable infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency. This is how we advance our mission of empowering breakthroughs in care through imaging.”

At RSNA this year, DeepHealth showcases an expanded, integrated portfolio of AI-powered solutions that demonstrate real-world impact in addressing key healthcare challenges such as disconnected patient engagement, strained workforce, inconsistent clinical outcomes and technology, data and workflow fragmentation. 

Unifying the Imaging Experience 
DeepHealth connects siloed tools, teams, and workflows to automate and orchestrate key tasks in the end-to-end imaging experience. DeepHealth showcases these solutions at RSNA through its enterprise imaging and operations portfolio that includes: 

• Diagnostic Suite™¹ — Accelerating and Automating Radiology: DeepHealth’s cloud-first enterprise image management and interpretation solutions deliver capabilities to automate and accelerate radiology at scale. New functionalities include cloud and hybrid data management with rapid migration, scalable ultra-fast streaming diagnostic viewer, AI-powered automated reporting and integrated advanced visualization, and enterprise AI orchestration in one seamless diagnostic environment. The recent acquisition of CIMAR UK brings additional advanced cloud image management and interoperability capabilities, supporting expanded deployments across the UK and Europe to accelerate AI-powered imaging, reporting and image-based screening. Components of Diagnostic Suite are actively deployed across RadNet sites and other customers, reflecting the Suite’s ability to deliver impact at scale in both outpatient and teleradiology environments. 
  
• TechLive™ — Expanding Capacity and Access: TechLive is a multimodality, vendor-agnostic remote imaging and radiology management solution. With first-of-kind 510(k) clearance, it extends expert oversight across MR, Ultrasound, CT and PET/CT to accelerate onboarding, meet diverse workforce needs and expand access to advanced imaging.² Deployment at RadNet to date has connected more than 400 scanners to TechLive, with results showing 42% fewer MR room closures, driving higher throughput and better patient and technologist experiences.² TechLive is available as a standalone solution or through an expanded collaboration with GE HealthCare for use with its ultrasound products. In addition, TechLive can be combined with Alpha RT as remote-scanning technology with staffing and training expertise to support diverse workforce and operational needs. 
  
• Operations Suite™ — Intelligent, Connected Imaging Operations: DeepHealth’s Operations Suite is an expanded, cloud-first suite of solutions that unifies scheduling, registration, billing, analytics and patient communication into a single environment. The Suite introduces new Patient Engagement solutions designed to improve communication, scheduling and adherence, along with agentic AI capabilities that enable automation to reduce administrative burden, optimize throughput and improve system-wide coordination. Operations Suite is being deployed across RadNet and other customer sites, as recently announced. Current customers leveraging DeepHealth RIS, previously eRAD RIS, will have the option to transition to Operations Suite through updated functionalities. 
  

Advancing Population Health with Clinical AI Solutions 
DeepHealth is introducing major advancements across its Population Health & Clinical AI portfolio, supported by expanded and new FDA clearances across multiple clinical areas. These innovations are designed to help stage shift disease, drive more timely and effective screening and diagnostic pathways, and expand patient access: 

• DeepHealth Breast Suite — Elevating Breast Cancer Detection and Diagnosis: The new Breast Suite³ an AI-powered, FDA-cleared end-to-end suite of modular interoperable applications that significantly enhances diagnostic accuracy,⁴ improve workflow efficiency and drive greater standardization of care.^4,5 Breast Suite delivers one of the industry’s most comprehensive breast cancer detection and diagnostic offerings by including breast cancer detection, risk asssesment,⁶ breast density, workflow tools and, in development, breast arterial calcification assessment.⁷ Breast Suite builds on organic innovation and technology integrated through the acquisition of iCAD to deliver a comprehensive new suite of solutions.
  • Breast Suite applications already support annually more than 10 million mammograms globally.
  • The largest real-world analysis of AI-powered breast cancer screening in the US recently published in Nature Health demonstrated the effectiveness of applications within Breast Suite to deliver a 21% increase in breast cancer detection rate in over 579,000 women, with consistent benefits across dense-breast and diverse patient populations.⁴
  • DeepHealth and GE HealthCare will expand their existing collaboration to include a wider suite of AI tools and extend access to the combined offering of their mammography systems with DeepHealth Breast Suite worldwide.
• DeepHealth Thyroid Suite — Transforming Thyroid Ultrasound Imaging: The Thyroid Suite,⁸ an AI-powered suite of modular applications seamlessly integrates into existing thyroid ultrasound workflows and technology, automating measurements and characterization^9,10 and significantly improving workflow efficiency.¹¹ By automating nodule detection, characterization and standardizing worksheets and reporting, Thyroid Suite applications help radiologists and sonographers work more efficiently and consistently. Thyroid Suite builds on organic innovation and technology integrated through the acquisition of See-Mode to deliver a new suite of solutions. Deployment across more than 200 sites within RadNet has demonstrated transformative real-world impact: radiologists interpreting more than 4,070 nodules accepted AI-based measurements and characterization without correction in greater than 94% of the cases.¹² The solution supports all ultrasound manufacturers and is available standalone or through the recently announced partnership with GE HealthCare’s ultrasound imaging.
• DeepHealth Neuro Suite — Quantifying Structural Changes for Proactive Care: The Neuro Suite¹³ applications automate and standardize neuroimaging analysis. It includes the FDA-cleared applications: Brain Health for white matter hyperintensity (WMH) detection and segmentation and Brain Age for volumetric measurement. By automatically quantifying key structures — including the hippocampus, lobes and subcortical regions — Neuro Suite tracks longitudinal progression to support proactive care.
• DeepHealth Chest Suite — Stage Shifting Lung Cancer: The applications of the expanded Chest Suite,¹⁴ previously referred to as DeepHealth Lung, automate pulmonary nodule detection, characterization and volumetric quantification, as well as standardize reporting and longitudinal tracking. These automations support radiologists in identifying disease earlier and improving diagnostic accuracy,^15,16 Chest Suite applications continue to enable population-scale screening programs worldwide, including NHS England’s Lung Cancer Screening Program for which UK Government data show that 76% of detected cancers are now caught at earlier, more treatable stages, compared to only 29% historically.¹⁷ Applications within the Chest Suite are cleared in Europe and the UK and are currently US 510(k)-pending, with plans to expand availability to US clinical sites.
• DeepHealth Prostate Suite — Advancing Diagnosis of Prostate Cancer: The next generation Prostate Suite¹⁸ streamlines prostate MRI interpretation, analysis and biopsy planning workflows. The suite integrates automated lesion detection and risk classification (510K pending), intelligent gland segmentation with PSA density calculation, and PI-RADS-compliant reporting into a single platform, delivering diagnostic accuracy¹⁹ and standardization of care.¹⁹ From initial scan review to targeted biopsy handoff, the solution connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer while supporting radiologists at every step. The Suite supports customer programs in the US and was recently selected to support the TRANSFORM prostate screening trial in the UK. 
  
• AI Studio — Enabling a Sustainable and Responsible AI Ecosystem: AI Studio, developed in partnership with CARPL and RagaAI, unifies a range of ecosystem AI solutions and enables seamless orchestration of these applications directly within the clinical workflow for automation and AI-powered care. AI Studio can integrate 140+ AI algorithms from 75+ ecosystem vendors, along DeepHealth’s own clinical AI solutions, directly into the worklist, viewer, reporting and workflow engine. The system includes governance tools for AI evaluation, monitoring and drift management in production, ensuring consistent performance and safe, reliable deployment at scale. 
  

At the core of this portfolio is DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics and AI suites into one unified environment. The OS delivers personalized, role-based experiences with seamless access to clinical and operational data, meeting the needs of every participant in the imaging workflow. With all solutions running on one cloud-native or hybrid platform, deployment, operations, security and infrastructure management are greatly simplified for IT professionals implementing tech solutions in healthcare. 

DeepHealth works with leading OEMs, cloud, AI, and platform partners to unify previously fragmented tools into a connected, end-to-end imaging experience. Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 2,000 customers and more than 5,000 radiologists leveraging its current solutions to deliver better care. 

DeepHealth’s portfolio²⁰ is presented in scientific sessions and at Booth #1329, South Hall, Level 3 at McCormick Place in Chicago. Anchoring the space will be an Experience Theater where visitors can experience interactive, hands-on educational lectures illustrating how AI is being integrated into practice across diverse clinical and operational areas. The Theater will also feature live sessions and panel discussions with clinical collaborators, technology partners and research leaders sharing insights from real-world AI deployments and upcoming technological advancements. 

Explore more about DeepHealth’s presence at RSNA 2025 and view the full schedule of live Experience Theater sessions at deephealth.com/rsna. 

About DeepHealth 
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, prostate, neuro, and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com 

About RadNet, Inc. 
RadNet, Inc. is a leading provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. https://radnet.com

Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the unifying clinical and operational intelligence into one system and enabling rapid-scale infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency, discussions regarding our product feature, and statements regarding our recent acquisitions. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
andra.axente@deephealth.com

RadNet Media Contacts 
Jane Mazur 
SVP, Corporate Communications
+1 585-355-5978 
jane.mazur@radnet.com 

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References 

1. Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components. 
2. Data on file. In a pilot deployment at 64 locations inside of RadNet’s New York area facilities, TechLive™ significantly contributed to a 27% increase in advanced breast MRI as a result of using DeepHealth’s TechLive remote scanning capability across 33 MR systems at RadNet NY centers since Feb 2025. 
3. Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Risk Assessment is not cleared for use in the U.S. BAC is in development; regulatory submission planned prior to the end of 2025. Not cleared for use in the US. Not all products and functions are available in all markets. Any claims made about Breast Suite may reference claims associated with its individual components.
4. Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025. 
5. McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025. 
6. Not cleared for use in the U.S. Capability available in Europe. 
7. In development, regulatory submission planned prior to the end of 2025. Not cleared for use in the US. 
8. DeepHealth Thyroid Suite comprises multiple applications including DeepHealth Viewer and DeepHealth Thyroid AI. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth. DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and Distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.
9. Data on file. Summary of Performance Testing Studies, Thyroid 510(k) clearance. 
10. Data on file. “Evaluation of AI-enhanced Thyroid Ultrasound Reporting Software for Improved Diagnostic Consistency.”
11. Data on file. DeepHealth’s Thyroid AI demonstrated up to a 30% reduction in scan slot time. Initial deployment at RadNet outpatient imaging centers.
12. Data on file. Results are based on data from 240+ RadNet sites and 22,000 thyroid studies.
13. Neuro Suite comprises multiple applications including Brain Health, Brain Age and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD and distributed by DeepHealth. Any claims made about Neuro Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
14. Chest Suite comprises multiple applications including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng. Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc. Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the US. HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc. DeepHealth Lung AI is 510(k) pending. Not all products and functions are available in all markets.
15. Identifies solid and sub-solid nodules (3-30mm) with 91% sensitivity, 1 false positive per scan. Setio et al. “Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules….” Med Image Anal. Dec 2017. 
16. Increases agreement (κ up to 0.82), reduces reading time up to 42%. Hempel et al. “Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules o….” Eur J RadiolOpen. Aug 2022. 
17. Mouland et al. “Targeted Lung Health Check Programme Final evaluation report.” Ipsos. November 2024.
18. DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending. Any claims made about Prostate Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
19. Data on file. DeepHealth pivotal study for FDA 510(k) clearance of Prostate AI, 12-reader by 250-case MRMC study and standalone testing on the same 250 exams.
20. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact a DeepHealth representative.

FAQ

What did DeepHealth announce at RSNA 2025 for RDNT investors?

DeepHealth unveiled expanded Imaging OS, Diagnostic, Operations and Clinical AI suites on Nov 30, 2025 to scale AI-powered imaging across sites.

How many scanners are connected to DeepHealth TechLive and what’s the impact?

TechLive has connected more than 400 scanners and is reported to reduce MR room closures by 42%.

What evidence supports DeepHealth Breast Suite effectiveness (RDNT)?

A Nature Health analysis covering >579,000 women showed a 21% increase in breast cancer detection using applications within Breast Suite.

Is DeepHealth Chest Suite available in the US now (RDNT)?

No—Chest Suite applications are cleared in Europe/UK but are currently US 510(k)-pending and not yet broadly available in the US.

How widely is Thyroid Suite deployed within RadNet (RDNT)?

Thyroid Suite is deployed across more than 200 sites within RadNet with >94% AI measurement acceptance observed in a 4,070-nodule sample.

What is DeepHealth OS and why does it matter for RDNT?

DeepHealth OS is a cloud-native platform unifying imaging, AI orchestration and workflows to simplify deployment and scale across enterprise sites.